相关实验视频

Updated: Feb 19, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

基于单一确认性随机临床试验的中间和最终结果的有条件营销许可的统计概念

Xiaofei Liu^1,2, Nele Henrike Thomas¹, Elina Asikanius³

¹Institute for Biostatistics, Hannover Medical School, Hannover, Germany.

Pharmaceutical statistics

|February 17, 2026

概括

有条件的营销许可 (CMA) 提供了对新药的早期准入. 对CMA试验提出的双重主终点策略在统计学上是有缺陷的;为了更好地解释结果,建议使用组序列设计的共同主终点.

科学领域:

临床试验的设计
监管科学是一种监管科学.
生物统计学生物统计学

背景情况:

有条件的营销许可 (CMA) 促进了对新药的早期获取,以满足欧盟尚未满足的需求.
在转换为全面的营销许可证 (MA) 之前,CMA需要一个积极的利益风险比率和授权后的数据.
最近的一项建议建议,基于中间和最终终点,对CMA和MA决策进行一次试验,并对CMA和MA决策进行临时分析.

研究的目的:

对CMA提出的双重初级终点统计方法进行批评.
提出使用共主终点和组序列设计的替代统计框架.
在CMA的背景下,提高整体临床试验结果的解释.

主要方法:

批评双重主终点概念及其对1型错误控制的影响.
建议共主终点,每个通过标准组顺序设计进行评估.
使用瘤学III期试验的插图,将完全缓解 (CR) 作为中间值和整体存活率 (OS) 作为最终终点.

主要成果:

双重主要终点方法对成功的统计定义可能与临床评估不一致.
拟议的共同主终点策略是一个有效和灵活的替代方案.
拟议的方法对CMA应用的样本大小或中间分析时间的影响最小.

结论:

对CMA的双重初级终点方法在统计学上是可疑的.
通过组序列设计评估的共同初级终点可以更好地解释试验结果.
拟议的方法支持有效的药物开发,同时保持统计学严谨性和临床相关性.

关键词:

临床试验是指临床试验中的临床试验.有条件的营销许可证.同一主要终点的终点.决策能力决策能力具有双重主终点的初级终点.组序列设计组的设计.

更多相关视频

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

相关概念视频

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...